Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on December 19, 2018, covering events occurring on December 13, 2018, and December 14, 2018. The company is a Delaware corporation headquartered in Rockville, Maryland.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses on operational and regulatory events rather than financial performance.
Material Changes and Events
- Termination of Material Definitive Agreement: On December 13, 2018, the Company terminated a Lease Agreement with Rockside-700 LLC for a new headquarters at 700 Quince Orchard Road, Gaithersburg, Maryland. The termination resulted from a dispute over facilities in the approved site plan. The lease term had not commenced, the premises were unoccupied, and no material termination penalties were incurred.
- Regulatory Approval: On December 14, 2018, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application to expand the label for Oxtellar XR to include monotherapy treatment for partial-onset seizures.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future performance. The primary risk disclosed relates to the prior dispute over the headquarters lease, which has been resolved via termination without financial penalty. The FDA approval represents a positive development for the company's product portfolio.
Investor Verification Checklist
- Verify the commercial impact of the expanded Oxtellar XR label for monotherapy treatment on future revenue projections.
- Confirm the Company's current status regarding headquarters location and any new lease agreements following the termination of the Rockside-700 LLC lease.
- Review the full text of the press release (Exhibit 99.1) for additional details on the FDA approval scope and marketing plans.